文献速递前列腺癌男科与性医学

临床路径改善前列腺癌患者ADT副作用管理循证策略的实施

Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer.
PubMed 文献 · BJU Int · 2018-01-10

该研究评估前列腺癌临床路径对ADT诱导副作用管理循证策略实施的影响。2015年医院层面引入临床路径,回顾性提取2014年(对照组)和2015年(干预组)接受ADT超过6个月患者的数据。结果显示干预组代谢、骨骼和心脏风险评估筛查及预防副作用建议的提供频率均显著高于对照组。

要点

  • 临床路径实施后代谢风险评估筛查从4%提升至46%,骨骼评估从10%提升至58%,心脏评估从16%提升至61%(P<0.001)。
  • 运动建议从11%提升至62%,营养建议从10%提升至58%,心理教育从13%提升至54%(P<0.001)。
  • 临床路径可作为缩小循证指南与日常临床实践差距的方法。

核心结论

  • 前列腺癌临床路径改善了ADT诱导副作用管理循证策略的实施,可作为连接循证指南与日常实践的桥梁。

研究设计与样本

  • 回顾性研究,纳入2014年对照组126例和2015年干预组132例接受ADT超过6个月的前列腺癌患者。

主要发现

  • 干预组代谢风险评估筛查46% vs 对照组4%,骨骼评估58% vs 10%,心脏评估61% vs 16%,均P<0.001。
  • 干预组运动建议62% vs 对照组11%,营养建议58% vs 10%,心理教育54% vs 13%,均P<0.001。

关键数值与推荐

  • 临床路径包含ADT诱导副作用管理的循证策略,适用于接受ADT超过6个月的前列腺癌患者。

临床怎么用

  • 医院层面引入临床路径可提高ADT副作用管理中循证策略的实施率。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effects of a prostate cancer (PCa) clinical pathway on the implementation of evidence-based strategies for the management of androgen deprivation therapy (ADT)-induced side effects. PATIENTS AND METHODS: A clinical pathway was introduced at hospital level in 2015. The pathway consists of evidence-based strategies for the management of ADT-induced side effects. All patients with PCa receiving ADT for >6 months were eligible to enter the clinical pathway. Data on recommended evidence-based strategies were retrospectively extracted from the electronic health records of all eligible patients in the year before (2014) and the year of implementation of the pathway (2015). Descriptive statistics were used for patient characteristics. The chi-squared test (or Fisher's exact test) and Mann-Whitney U-test were used to compare results in the control group with those in the intervention group. RESULTS: In total, 126 patients were included in the control group and 132 patients in the intervention group. Baseline patient characteristics were well balanced. After implementation of the pathway, metabolic, bone and cardiac risk assessment screenings were more frequently applied in the intervention group (metabolic 46% vs 4%; bone 58% vs 10%; cardiac 61% vs 16%; P < 0.001). Advice on strategies preventing ADT-induced side effects was more frequently provided in the intervention group (exercise 62% vs 11%; nutrition 58% vs 10%; psycho-education 54% vs 13%; P < 0.001). CONCLUSION: A clinical pathway for patients with PCa improved the implementation of evidence-based strategies for the management of ADT-induced side effects. A clinical pathway could serve as a method to bridge the gap between evidence-based guidelines and daily clinical practice.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Bultijnck R, Van de Caveye I, Rammant E, et al. Clinical pathway improves implementation of evidence-based strategies for the management of androgen deprivation therapy-induced side effects in men with prostate cancer. BJU Int. 2018. PMID: 29194928. doi:10.1111/bju.14086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。